The DOI matches its Crossref record.
A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Abstract
Alzheimer's disease (AD), a progressive, degenerative disorder of the brain, is believed to be the most common cause of dementia amongst the elderly. AD is characterized by the presence of amyloid deposits and neurofibrillary tangles in the brain of afflicted individuals. AD is associated with a loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning. AD appears to have a heterogeneous etiology with a large percentage termed sporadic AD arising from unknown causes and a smaller fraction of early onset familial AD (FAD) caused by mutations in one of several genes, such as the beta-amyloid precursor protein (APP) and presenilins (PS1, PS2). These proteins along with tau, secretases, such as beta-amyloid cleaving enzyme (BACE), and apolipoprotein E play important roles in the pathology of AD. On therapeutic fronts, there is significant research underway in the development of new inhibitors for BACE, PS-1 and gamma-secretase as targets for treatment of AD. There is also a remarkable advancement in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. The development of vaccination strategies, anti-inflammatory agents, cholesterol-lowering agents, anti-oxidants and hormone therapy are examples of new approaches for treating or slowing the progression of AD. In addition, nutritional, genetic and environmental factors highlight more effective preventive strategies for AD. Developments of early diagnostic tools and of quantitative markers are critical to better follow the course of the disease and to evaluate different therapeutic strategies. In this review, we attempt to critically examine recent trends in AD research from molecular, genetic to clinical areas. We discuss various neurobiological mechanisms that provide the basis of new targets for AD drug development. All these current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the AD brain in order to effectively diagnose and prevent their occurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Curcumin—From Molecule to Biological Function
Esatbeyoglu, T., Huebbe, P., Ernst, I. M. A., Chin, D., Wagner, A. E., & Rimbach, G. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107724 · Cited by 904
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734
Self-citationThe crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411
“…2003) and alternative approaches such as the inhibition of the expression of amyloidogenic protein (De Felice & Ferreira, 2002), inhibition of the release of amyloidogenic peptide and inhibition of Ab-amyloid aggregation (Conway et al., 2003; Lahiri et al., 2003; reviewed in Mason et al., 2003).”
BackgroundBasha, M. R., Wei, W., Bakheet, S. A., Benitez, N., Siddiqi, H. K., Ge, Y.-W., Lahiri, D. K., & Zawia, N. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4335-04.2005 · Cited by 349
Self-citationAmyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
“Unfortunately, all FDA approved treatments for AD only provide temporary cognitive improvement with negligible disease modifying effect on the neuropathology [2, 3].”
BackgroundSelf-citationTargeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 307
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
Epigenetic regulation in the pathophysiology of Alzheimer's disease
Chouliaras, L., Rutten, B. P. F., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. M., & van den Hove, D. L. A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.002 · Cited by 262
Han, X. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772786 · Cited by 183
Ray, B., Bisht, S., Maitra, A., Maitra, A., & Lahiri, D. K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101374 · Cited by 177
Self-citationBihaqi, S. W., Huang, H., Wu, J., & Zawia, N. H. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-111013 · Cited by 162
JNK Plays a Key Role in Tau Hyperphosphorylation in Alzheimer's Disease Models
Ploia, C., Antoniou, X., Sclip, A., Grande, V., Cardinetti, D., Colombo, A., Canu, N., Benussi, L., Ghidoni, R., Forloni, G., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110320 · Cited by 145
Role of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117
Ray, B., B. Chauhan, N., & K. Lahiri, D. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796504664 · Cited by 100
“In the final step of processing, C99 is cleaved by γ secretase to produce Aβ peptides, containing 39–43 amino acids residue [22].”
BackgroundHu, L., Wong, T. P., Côté, S. L., Bell, K. F. S., & Cuello, A. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00394-4 · Cited by 90
Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice
Zhou, J., Yang, W.-S., Suo, D.-Q., Li, Y., Peng, L., Xu, L.-X., Zeng, K.-Y., Ren, T., Wang, Y., Zhou, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00389 · Cited by 53
“However, the number of drugs approved for the treatment of AD patients with cognitive impairment is limited due to their side effects, which include pain, nausea and hepatotoxicity (Lahiri et al., 2003).”
BackgroundRetinoids for treatment of Alzheimer’s disease
Lerner, A. J., Gustaw‐Rothenberg, K., Smyth, S., & Casadesus, G. (2012) · BioFactors · doi:10.1002/biof.196 · Cited by 44
Asiatic acid derivatives enhance cognitive performance partly by improving acetylcholine synthesis
Kim, S. R., Koo, K. A., Lee, M. K., Park, H.-G., Jew, S.-S., Cha, K.-H., & Kim, Y. C. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044391 · Cited by 31
Adeniyi, I. A., Oregbesan, P. O., Adesanya, A., Olubori, M. A., Olayinka, G. S., Ajayi, A. M., & Onasanwo, S. A. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116995 · Cited by 5
Metadata
- Authors
- Lahiri, D., Farlow, M., Sambamurti, K., Greig, N., Giacobini, E., & Schneider, L.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 97-112
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W1989329391
- Cited by
- 185
- References
- 0
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.